Adjuvant and neoadjuvant approaches for urothelial cancer: Updated indications and controversies

Francesco Massari, Matteo Santoni, Vincenzo di Nunno, Liang Cheng, Antonio Lopez-Beltran, Alessia Cimadamore, Silvia Gasparrini, Marina Scarpelli, Nicola Battelli, Rodolfo Montironi

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Urothelial carcinoma (UC) of the bladder and upper urinary tract still results an open challenge for clinical oncologists. Excluding selected patients who will particularly benefit from chemo-radiotherapy combined to endoscopic tumour removal, surgery represents the only curative approach for localized stages. Unfortunately, over 50% of operated patients do experience local or distant recurrence of the disease. Several pre and/or postoperative treatments are under evaluation in patients with UC in order to effectively reduce the difficulty and morbidity of more extensive procedures and to increase the Disease-Free Survival (DFS). The number of trials has been rapidly increased by the development of immunocheckpoint inhibitors, used alone or in combined strategies with chemotherapy, radiotherapy or other immunotherapies. The aim of this review is to illustrate the current status of neoadjuvant and adjuvant treatments in UC focusing our attention to the major ongoing trials in these settings.

Original languageEnglish (US)
Pages (from-to)80-85
Number of pages6
JournalCancer Treatment Reviews
Volume68
DOIs
StatePublished - Jul 1 2018

Fingerprint

Carcinoma
Radiotherapy
Neoplasms
Neoadjuvant Therapy
Urinary Tract
Immunotherapy
Disease-Free Survival
Urinary Bladder
Morbidity
Recurrence
Drug Therapy
Therapeutics
Oncologists

Keywords

  • Adjuvant therapy
  • Clinical trials
  • Immunocheckpoint inhibitors
  • Neoadjuvant therapy
  • Urothelial cancer

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Massari, F., Santoni, M., di Nunno, V., Cheng, L., Lopez-Beltran, A., Cimadamore, A., ... Montironi, R. (2018). Adjuvant and neoadjuvant approaches for urothelial cancer: Updated indications and controversies. Cancer Treatment Reviews, 68, 80-85. https://doi.org/10.1016/j.ctrv.2018.06.002

Adjuvant and neoadjuvant approaches for urothelial cancer : Updated indications and controversies. / Massari, Francesco; Santoni, Matteo; di Nunno, Vincenzo; Cheng, Liang; Lopez-Beltran, Antonio; Cimadamore, Alessia; Gasparrini, Silvia; Scarpelli, Marina; Battelli, Nicola; Montironi, Rodolfo.

In: Cancer Treatment Reviews, Vol. 68, 01.07.2018, p. 80-85.

Research output: Contribution to journalReview article

Massari, F, Santoni, M, di Nunno, V, Cheng, L, Lopez-Beltran, A, Cimadamore, A, Gasparrini, S, Scarpelli, M, Battelli, N & Montironi, R 2018, 'Adjuvant and neoadjuvant approaches for urothelial cancer: Updated indications and controversies', Cancer Treatment Reviews, vol. 68, pp. 80-85. https://doi.org/10.1016/j.ctrv.2018.06.002
Massari, Francesco ; Santoni, Matteo ; di Nunno, Vincenzo ; Cheng, Liang ; Lopez-Beltran, Antonio ; Cimadamore, Alessia ; Gasparrini, Silvia ; Scarpelli, Marina ; Battelli, Nicola ; Montironi, Rodolfo. / Adjuvant and neoadjuvant approaches for urothelial cancer : Updated indications and controversies. In: Cancer Treatment Reviews. 2018 ; Vol. 68. pp. 80-85.
@article{2dc25d3ef93647e2ad7daa71d22e2856,
title = "Adjuvant and neoadjuvant approaches for urothelial cancer: Updated indications and controversies",
abstract = "Urothelial carcinoma (UC) of the bladder and upper urinary tract still results an open challenge for clinical oncologists. Excluding selected patients who will particularly benefit from chemo-radiotherapy combined to endoscopic tumour removal, surgery represents the only curative approach for localized stages. Unfortunately, over 50{\%} of operated patients do experience local or distant recurrence of the disease. Several pre and/or postoperative treatments are under evaluation in patients with UC in order to effectively reduce the difficulty and morbidity of more extensive procedures and to increase the Disease-Free Survival (DFS). The number of trials has been rapidly increased by the development of immunocheckpoint inhibitors, used alone or in combined strategies with chemotherapy, radiotherapy or other immunotherapies. The aim of this review is to illustrate the current status of neoadjuvant and adjuvant treatments in UC focusing our attention to the major ongoing trials in these settings.",
keywords = "Adjuvant therapy, Clinical trials, Immunocheckpoint inhibitors, Neoadjuvant therapy, Urothelial cancer",
author = "Francesco Massari and Matteo Santoni and {di Nunno}, Vincenzo and Liang Cheng and Antonio Lopez-Beltran and Alessia Cimadamore and Silvia Gasparrini and Marina Scarpelli and Nicola Battelli and Rodolfo Montironi",
year = "2018",
month = "7",
day = "1",
doi = "10.1016/j.ctrv.2018.06.002",
language = "English (US)",
volume = "68",
pages = "80--85",
journal = "Cancer Treatment Reviews",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Adjuvant and neoadjuvant approaches for urothelial cancer

T2 - Updated indications and controversies

AU - Massari, Francesco

AU - Santoni, Matteo

AU - di Nunno, Vincenzo

AU - Cheng, Liang

AU - Lopez-Beltran, Antonio

AU - Cimadamore, Alessia

AU - Gasparrini, Silvia

AU - Scarpelli, Marina

AU - Battelli, Nicola

AU - Montironi, Rodolfo

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Urothelial carcinoma (UC) of the bladder and upper urinary tract still results an open challenge for clinical oncologists. Excluding selected patients who will particularly benefit from chemo-radiotherapy combined to endoscopic tumour removal, surgery represents the only curative approach for localized stages. Unfortunately, over 50% of operated patients do experience local or distant recurrence of the disease. Several pre and/or postoperative treatments are under evaluation in patients with UC in order to effectively reduce the difficulty and morbidity of more extensive procedures and to increase the Disease-Free Survival (DFS). The number of trials has been rapidly increased by the development of immunocheckpoint inhibitors, used alone or in combined strategies with chemotherapy, radiotherapy or other immunotherapies. The aim of this review is to illustrate the current status of neoadjuvant and adjuvant treatments in UC focusing our attention to the major ongoing trials in these settings.

AB - Urothelial carcinoma (UC) of the bladder and upper urinary tract still results an open challenge for clinical oncologists. Excluding selected patients who will particularly benefit from chemo-radiotherapy combined to endoscopic tumour removal, surgery represents the only curative approach for localized stages. Unfortunately, over 50% of operated patients do experience local or distant recurrence of the disease. Several pre and/or postoperative treatments are under evaluation in patients with UC in order to effectively reduce the difficulty and morbidity of more extensive procedures and to increase the Disease-Free Survival (DFS). The number of trials has been rapidly increased by the development of immunocheckpoint inhibitors, used alone or in combined strategies with chemotherapy, radiotherapy or other immunotherapies. The aim of this review is to illustrate the current status of neoadjuvant and adjuvant treatments in UC focusing our attention to the major ongoing trials in these settings.

KW - Adjuvant therapy

KW - Clinical trials

KW - Immunocheckpoint inhibitors

KW - Neoadjuvant therapy

KW - Urothelial cancer

UR - http://www.scopus.com/inward/record.url?scp=85048559658&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048559658&partnerID=8YFLogxK

U2 - 10.1016/j.ctrv.2018.06.002

DO - 10.1016/j.ctrv.2018.06.002

M3 - Review article

C2 - 29886353

AN - SCOPUS:85048559658

VL - 68

SP - 80

EP - 85

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

ER -